Alabama Among Others to Test Psilocybin Treatment for Veterans

Alabama among others to test Psilocybin treatment for veterans

Two sites in Alabama will be among others for the U.S. Department of Veterans Affairs (VA) to test the effects of psilocybin therapy for veterans with PTSD and depression. According to Alabama Political Reporter, the program is named the Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression. Researchers will study the effects on veterans with a double-blind, randomized controlled trial. The study was authorized some time…

Alabama VA facilities to study psilocybin for depression treatment

The Birmingham and Tuscaloosa VA facilities are among five sites testing psilocybin as a potential treatment for veterans with depression.

A fast-acting psychedelic shows promise for postpartum depression

A single day of treatment with an inhaled psychedelic compound called mebufotenin helped relieve symptoms of postpartum depression in a small trial of new mothers. Within two hours of receiving the therapy, patients experienced a near-total reduction in depressive symptoms that lasted for the weeklong duration of the study. The research was published in The Journal of Clinical Psychiatry. Postpartum depression is a severe mood disorder affecting…

VA launches national psilocybin therapy trial with Birmingham, Tuscaloosa sites

Birmingham and Tuscaloosa VA researchers will test whether pharmaceutical-grade psilocybin can ease treatment-resistant depression and PTSD in veterans.

Single-dose psilocybin shows promise for treatment-resistant depression in NHS trial

A single 25-mg dose of psilocybin with psychological support was feasible to deliver within an NHS setting and produced large preliminary reductions in depressive symptoms among adults with treatment-resistant depression. The Phase 2 feasibility trial also found the treatment was generally well tolerated, although functional unblinding and expectancy effects mean larger, longer efficacy studies are needed.

25mg Mushroom Shock: Big Lift, Big Questions | Fresh Off The Press

Magic mushrooms’ key psychedelic ingredient is showing real short-term relief for stubborn depression, but the evidence is still not practice-ready. Quick Take King’s College London is running a phase 2 trial of psilocybin for treatment-resistant depression. The main study uses a single 25 milligram dose with psychological therapy. A larger multicentre trial found better depression scores with 25 milligrams than with the low-dose control. Resea…